• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing.

作者信息

Lim Ken-Hong, Wu Jo-Ning, Huang To-Yu, Jhuang Jie-Yang, Chang Yu-Cheng, Lin Huan-Chau, Chiang Yi-Hao, Su Ying-Wen, Chen Caleb Gon-Shen, Chang Yi-Fang, Lin Johnson

机构信息

Division of Hematology and Oncology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.

Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.

出版信息

Blood Adv. 2021 Mar 23;5(6):1733-1736. doi: 10.1182/bloodadvances.2020003980.

DOI:10.1182/bloodadvances.2020003980
PMID:33734329
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7993095/
Abstract
摘要

相似文献

1
Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing.单细胞DNA测序揭示晚期系统性肥大细胞增多症中的克隆进化和异质性
Blood Adv. 2021 Mar 23;5(6):1733-1736. doi: 10.1182/bloodadvances.2020003980.
2
Kit Mutations: New Insights and Diagnostic Value.试剂盒突变：新见解与诊断价值
Immunol Allergy Clin North Am. 2018 Aug;38(3):411-428. doi: 10.1016/j.iac.2018.04.005. Epub 2018 Jun 9.
3
Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: a case review.伴有相关克隆性血液非肥大细胞谱系疾病的系统性肥大细胞增多症：病例回顾
Am J Hematol. 2012 Feb;87(2):191-3. doi: 10.1002/ajh.22208. Epub 2011 Nov 12.
4
Systemic mastocytosis associated with two clonal haematological neoplasms.系统性肥大细胞增多症合并两种克隆性血液肿瘤。
Pathology. 2022 Apr;54(3):361-363. doi: 10.1016/j.pathol.2021.06.117. Epub 2021 Aug 18.
5
Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.外周血中循环的 KIT D816V 突变阳性非肥大细胞是惰性系统性肥大细胞增多症的特征。
Eur J Haematol. 2012 Jul;89(1):42-6. doi: 10.1111/j.1600-0609.2012.01789.x. Epub 2012 Apr 28.
6
Cytology of systemic mastocytosis.系统性肥大细胞增多症的细胞学
Am J Hematol. 2009 Dec;84(12):842. doi: 10.1002/ajh.21535.
7
The genetic basis of mast cell activation disease - looking through a glass darkly.肥大细胞活化疾病的遗传学基础——雾里看花。
Crit Rev Oncol Hematol. 2015 Feb;93(2):75-89. doi: 10.1016/j.critrevonc.2014.09.001. Epub 2014 Sep 28.
8
Systemic mastocytosis.系统性肥大细胞增生症。
Hematol Oncol Clin North Am. 2011 Oct;25(5):1067-83, vii. doi: 10.1016/j.hoc.2011.09.012.
9
Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.色素性荨麻疹演变为惰性系统性肥大细胞增多症：肥大细胞免疫表型异常，无c-kit突变ASP-816-VAL证据
Leuk Lymphoma. 2003 Feb;44(2):313-9. doi: 10.1080/1042819021000037967.
10
A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.一种使用分泌型荧光素酶监测的KIT D816V+晚期系统性肥大细胞增多症的新型人源化体内模型。
Oncotarget. 2016 Dec 13;7(50):82985-83000. doi: 10.18632/oncotarget.12824.

引用本文的文献

1
Prevalence of myeloid gene alterations in paediatric cutaneous and systemic mastocytosis.儿童皮肤和系统性肥大细胞增多症中髓系基因改变的患病率。
Br J Haematol. 2025 Jun 19. doi: 10.1111/bjh.20214.

本文引用的文献

1
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.晚期系统性肥大细胞增多症的诊断、预后和治疗的新进展。
Blood. 2020 Apr 16;135(16):1365-1376. doi: 10.1182/blood.2019000932.
2
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.MARS：晚期系统性肥大细胞增多症的突变调整风险评分。
J Clin Oncol. 2019 Nov 1;37(31):2846-2856. doi: 10.1200/JCO.19.00640. Epub 2019 Sep 11.
3
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.成人系统性肥大细胞增生症：诊断、危险分层和治疗的 2019 年更新。
Am J Hematol. 2019 Mar;94(3):363-377. doi: 10.1002/ajh.25371. Epub 2019 Jan 2.
4
Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models.梅奥联盟肥大细胞增多症预后系统：临床和混合临床-分子模型。
Blood Adv. 2018 Nov 13;2(21):2964-2972. doi: 10.1182/bloodadvances.2018026245.
5
SRSF2 mutations in myelodysplasia/myeloproliferative neoplasms.骨髓增生异常综合征/骨髓增殖性肿瘤中的SRSF2突变
Biomark Res. 2018 Sep 26;6:29. doi: 10.1186/s40364-018-0142-y. eCollection 2018.
6
Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.米哚妥林：一种用于FLT3突变的急性髓系白血病和系统性肥大细胞增多症患者的新型治疗药物。
Ther Adv Hematol. 2017 Sep;8(9):245-261. doi: 10.1177/2040620717721459. Epub 2017 Aug 19.
7
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.中剂量罗替尼治疗晚期系统性肥大细胞增多症患者的疗效和安全性：一项 II 期试验的 10 年中位随访。
Leukemia. 2018 Feb;32(2):470-478. doi: 10.1038/leu.2017.234. Epub 2017 Jul 24.
8
Response and progression on midostaurin in advanced systemic mastocytosis: D816V and other molecular markers.中剂量伊马替尼治疗晚期系统性肥大细胞增生症的反应和进展：D816V 及其他分子标志物。
Blood. 2017 Jul 13;130(2):137-145. doi: 10.1182/blood-2017-01-764423. Epub 2017 Apr 19.
9
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.伴有或不伴有相关血液系统肿瘤的肥大细胞白血病的临床和分子多样性。
Haematologica. 2017 Jun;102(6):1035-1043. doi: 10.3324/haematol.2017.163964. Epub 2017 Mar 2.
10
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.中剂量伊马替尼治疗晚期系统性肥大细胞增多症的疗效和安全性。
N Engl J Med. 2016 Jun 30;374(26):2530-41. doi: 10.1056/NEJMoa1513098.